XOMA Corporation (NASDAQ: XOMA) is one of 95 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare XOMA Corporation to related companies based on the strength of its institutional ownership, valuation, profitability, analyst recommendations, risk, earnings and dividends.
Earnings & Valuation
This table compares XOMA Corporation and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|XOMA Corporation||$12.31 million||-$30.55 million||-3.22|
|XOMA Corporation Competitors||$224.52 million||$58.08 million||-1.10|
XOMA Corporation’s competitors have higher revenue and earnings than XOMA Corporation. XOMA Corporation is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
32.9% of XOMA Corporation shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 3.0% of XOMA Corporation shares are held by insiders. Comparatively, 18.5% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Volatility & Risk
XOMA Corporation has a beta of 3.2, indicating that its share price is 220% more volatile than the S&P 500. Comparatively, XOMA Corporation’s competitors have a beta of 1.13, indicating that their average share price is 13% more volatile than the S&P 500.
This table compares XOMA Corporation and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|XOMA Corporation Competitors||-910.58%||-183.99%||-27.07%|
This is a summary of current ratings and target prices for XOMA Corporation and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|XOMA Corporation Competitors||123||463||1161||11||2.60|
XOMA Corporation currently has a consensus price target of $28.50, indicating a potential upside of 20.87%. As a group, “Biotechnology” companies have a potential upside of 67.34%. Given XOMA Corporation’s competitors stronger consensus rating and higher probable upside, analysts clearly believe XOMA Corporation has less favorable growth aspects than its competitors.
XOMA Corporation competitors beat XOMA Corporation on 8 of the 12 factors compared.
About XOMA Corporation
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with our FREE daily email newsletter.